Clinical trial
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate…
NCT00439270 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00439270 |
|---|---|
| Title | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer |
| Official title | Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Dasatinib, Docetaxel |
| Enrollment | 49 |
| Start date | Jul 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Feb 23, 2007 |
| Last update posted | Mar 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: